New and improved services will provide unprecedented depth, precision and throughput to quantify up to 3,000 proteins in plasma or serum
Biognosys, a leader in drug discovery and development of proteomics solutions, today announced the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service. The service is designed to help researchers decipher the complexity of blood proteome, and open unbiased discoveries for pharmaceutical and diagnostic development and precision medicine.
This conference will launch a series of Activities and resources The science and technology behind the new solution and its application are introduced in detail:
- Start the webinar On November 9, it was titled: “Plasma proteomics: the next frontier of biomarker discovery in the era of precision medicine.”
Displays and exhibitions at fairs Society for Cancer Immunotherapy (SITC) Annual Meeting November 12-14 in Washington, D.C.
The new service provides unprecedented depth, quantitative accuracy, and throughput for discovery research. The solution will search the complete plasma proteome to quantify up to 3,000…